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Abstract 
Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis are adverse hypersensitivity reactions that affect 
the skin and mucous membranes. They are characterised by erythematous macules and hemorrhagic erosions of 
the mucous membranes. Epidermal detachments of varying degrees of severity also occur in these conditions. 
Various aetiologies are associated with these conditions, with adverse drug reaction being the most common. 
Though the worldwide incidence of these conditions is recorded as low, diverse types of medication are being 
observed to lead to these conditions. This review compiles information on the details of Stevens-Johnson 
syndrome and Toxic Epidermal Necrolysis, the pathophysiology, therapeutic management, and largely considers 
the drug-induced etiologies associated with these conditions. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Stevens-Johnson syndrome (SJS) is a 
dermatological condition with the more severe form 
being toxic epidermal necrolysis syndrome (TEN) or 
Lyell’s syndrome. These two syndromes are said to 
exist at the two ends of the spectrum of an adverse 
skin reaction occurring from severe epidermolysis [1]. 
They present as severe exfoliative reactions affecting 
mainly the skin and mucous membranes [1]. The 
characteristic clinical presentation includes 
mucocutaneous tenderness, hemorrhagic erosions, 
and erosion of the mucous membrane, 
erythematous macules, blisters and denuded skin 
occurring as a result of the severe separation of the 
epidermis from the dermis [2]. The Bastuji-Garin et 
al. criterium is used in the diagnosis of SJS/TEN in 
which patients are classified into three categories 
based on the degrees of skin detachment [2], while 
the international classification uses the affected 
body surface area (BSA); SJS involves lower than 
10% of the BSA, while TEN affects greater than 30% 
of the BSA. The definition of SJS and TEN 
incorporates an overlap which shall be highlighted in 
Table 1 below. It has been shown that SJS and TEN 
have mortalities in the range of 10 to 50 percent [3].  
SJS/TEN can present in any age group but 
occurs more frequently in women, HIV-Infected 
patients, and the elderly. The global incidence rate 
associated with TEN is low, estimated in 2005 
between 0.4 and 1.2 or 1.3 per million persons yearly. 
An epidemiologic study of TEN in France gave a 
similar incidence of 1 to 1.3 cases/million/ annum [4]. 
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However, as the years’ advance, the numbers of 
incidence seem to be increasing in other parts of the 
world. Literature shows a correlation between the 
incidence and increasing age. The incidence 
increases sharply with increasing age, as does the 
use of drugs with ageing [5]. Females are most 
commonly affected represented by a female-male 
ratio of 3:2. The average age of patients reported is 
between the ages of 46 and 63, while the proportion 
of females is estimated between 61.3% and 64.3%, 
respectively [4]. Reports have also been linked to 
patients with Human Immunodeficiency Virus (HIV)-1 
infection, recipients of bone-marrow transplants and 
systemic lupus erythematosus (SLE) [5]. 
Drug hypersensitivity has been associated 
with relatively complex genetic factors, which have 
been studied in diverse populations as well as in a 
variety of ethnic background. Chung et al., 
demonstrated a uniquely strong correlation between 
drug hypersensitivity (Carbamazepine triggered SJS), 
ethnic background (Hans Chinese) and Human 
Leucocyte Antigen (HLA)-B*1502 [3]. This strong 
association resulted in a further investigation into a 
similar cohort of Hong Kong Han Chinese having 
severe adverse cutaneous reactions to anticonvulsant 
drugs [6].  
In another study of a Thai population, the 
susceptibility of individuals with HLA-B*1502 to the 
anticonvulsant carbamazepine was confirmed [7]. 
However, a weak association between 
carbamazepine and HLA-B*1502 was only 
demonstrable in an Indian-based study. While no 
genetic correlation could be established in Europeans 
and Japanese [8][9].  
To further corroborate this non-genetic 
association in Europeans, a large study (RegiSCAR) 
carried out an HLA-B genotype on patients who 
suffered severe adverse cutaneous reactions 
triggered carbamazepine, lamotrigine, 
sulfamethoxazole, allopurinol, and NSAIDs of oxicam-
type regarded as high-risk drugs. The study showed 
that HLA-B*1502 is not a confirmatory marker for any 
of the studied high-risk drugs known to cause 
SJS/TEN, and hence cannot be authoritatively 
labelled the cause of pathology in Europeans [10][11]. 
Therefore, it can be concluded that for SJS/TEN in 
individuals exposed to Carbamazepine, “the genetic 
constellation of HLA-B*1502 is not a population 
independent marker” [6]. 
HLA-B*5801 is another genotype which has 
been highly correlated with SJS/TEN in Han Chinese 
patients exposed to allopurinol. The study showed a 
100% correlation of allopurinol exposure to HLA -
B*5801 positive genotype in patients who presented 
with the adverse drug reactions [12]. Subsequent 
studies further revealed a high correlation between 
HLA-B*5801 and SJS/TEN in Thai patients [7], 
Japanese patients [9], and too much lower degree 
patients of European descent (about 55% of cases) 
[11]. 
Epidermal necrosis that occurs as a part of 
the TEN disease process is mainly associated with 
massive keratinocyte apoptosis [4]. This is mediated 
by surface receptors such as tumour necrosis factor 
(TNF) receptor (Fas), and when coupled with the Fas 
ligand causes disassembly of DNA and cell death by 
the induction of apoptosis [7]. Cell death could also be 
modulated by death receptor-independent 
mechanisms that include the release granzyme-B and 
perforins from cytotoxic T lymphocytes, thus activating 
the caspase-dependent or caspase-independent 
mechanism [12].  
 
 
Clinical Presentation 
 
The initial presentation of SJS/TEN may 
include non-specific symptoms such as fever, 
discomfort with swallowing, and stinging eyes. 
Typically, the cutaneous manifestations of SJS/TEN 
are usually preceded by these non-specific symptoms 
[13] [14]. Early locations for skin involvement include 
the presternal truncal region, the face, and could also 
involve the palms and the soles. In about 90% of 
patients, there is involvement of the mucosa of the 
mouth, genital and/or gastrointestinal tracts visible as 
erythema and erosions [13] [14]. Other frequent 
presentations at the beginning of the pathology is eye 
related and this ranges from acute conjunctivitis, 
erythema, edema of the eyelid, ocular discharge and 
crusting, to corneal erosion, the formation of 
conjunctival membrane or pseudomembrane, and in 
severe cases, to corneal ulcerations, cicatrizing 
lesions, fornix shortening, and symblepharon [15] [16]. 
However, late complications of SJS/TEN cannot be 
predicted by the severity of acute ocular 
manifestations [17]. Erythematous and livid macules 
typify the morphology of early cutaneous lesions. 
Table 1: Clinical manifestations distinguishing SJS, SJS-TEN 
overlap, and TEN [2] 
Clinical entity SJS SJS-TEN overlap TEN 
Primary Lesions Dusky red lesions Dusky red lesions Poorly delineated 
erythematous plaques 
 Flat atypical targets Flat atypical targets Epidermal detachment 
   Dusky red lesions 
   Flat atypical targets 
Distribution Isolated lesions Isolated lesions Isolated lesions (rare) 
 Confluence (+) on 
face and trunk 
Confluence (++) on 
face and trunk 
Confluence (+++) on face, 
trunk, and elsewhere 
Mucosal 
involvement 
Yes Yes Yes 
Systemic symptoms Usually Always Always 
Detachment (%body 
surface area) 
< 10 10-30 > 30 
 
The second phase is characterised by the 
development of wide-spread areas of epidermal 
separation. If no epidermal separation is observed, it 
warrants more detailed skin examination during which 
a tangential mechanical pressure is exerted on many 
erythematous areas, called Nikolsky sign. If the 
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mechanical pressure causes and epidermal 
detachment, Nikolsky sign is positive. However, 
Nikolsky sign is not only defined for SJS or TEN, as it 
can equally be positive in conditions like the 
autoimmune bullous cutaneous pathologies like the 
pemphigus vulgaris [15] which can be utilised as a 
distinguishing feature from a similar autoimmune 
condition, bullous pemphigoid.  
A major prognostic factor is the degree of 
cutaneous involvement. The evaluation of the degree 
of skin involvement should only include the already 
detached necrotic skin or detachable skin, that is, 
those that are Nikolsky positive [17].  
Magina and colleagues [16] reported the 
following presentations for the late phase of TEN: 
Cutaneous hypo and hyperpigmentation (62.5%), nail 
dystrophies (37.5%), and the rest being eye 
complications. In another study, Yip et al. reported 
late ocular complications in about 50% of patients with 
TEN and reported them by ranking them in decreasing 
frequencies; “severe ocular dryness (46% of cases), 
trichiasis (16%), symblepharon (14%), distichiasis 
(14%), visual loss (5%), entropion (5%), 
ankyloblepharon (2%), lagophthalmos (2%), and 
corneal ulceration (2%)” [18]. Hypertrophic scars have 
only been reported in a handful of patients [19]. 
Reports have shown that 73% of patients with acute 
phase mucosal involvement subsequently presented 
with long-term complications with mucosal sequelae 
involving the oral and oesophagal mucosa majorly, 
and to a lesser degree, the genital and pulmonary 
mucosa [20]. Similarly, a nine-patient SJS/TEN study 
showed seven of the patients presenting with either 
keratoconjunctivitis or xerostomia or both, with a 
resemblance to Sjogren-like syndrome [21]. 
Furthermore, another report revealed a patient with 
“Sjögren-like pluriglandular exocrine insufficiency”, 
which is also resulted in an impairment of the exocrine 
pancreas [22].  
 
 
Drug etiologies associated with SJS and 
TEN 
 
A major percentage of the disease is caused 
by medications, while the remaining is due to upper 
respiratory infections such as HIV [23], Hepatitis virus, 
Herpes virus, Mycoplasma pneumoniae [24] [25]. 
Others include malignancies, as well as idiopathic. A 
substantial number of medications have been 
implicated in the aetiology of SJS/TEN. This article 
has attempted to review as many as possible of the 
published reports. The table 2 below summarises 
some drug categories that have been implicated in the 
aetiology of SJS/TEN. 
 
Table 2: Reported cases of drug-induced sjs/ten 
Drug Classification References 
Antibiotics 23-34 
Anticonvulsants 35-41 
Sulfonylureas 42 
Diuretics 43-44 
Analgesics 45-48 
Antidepressants 49-50 
Tyrosine Kinase Inhibitors 51-54 
Xanthine Oxidase Inhibitors 55 
Androgenic hormones 56-57 
Antineoplastic drugs 58-60 
Antiviral drugs 61-63 
Combination drug(Aggrenox) 64 
Immunosuppressant/modulators 65-67 
Antihistamines 68 
Angiotensin-converting enzyme inhibitors 69 
Anti-osteoporotic agent 70 
Contrast agent 71 
Insecticide 72-73 
 
 
Antibiotics 
Sulfonamides: Among the antibiotics, the 
most implicated high-risk cause of SJS/TEN are the 
sulfonamides especially Trimethoprim -
Sulfamethoxazole which accounts for about 69% of 
cases. The other non-sulfonamide antibiotics are 
considered low risk [23] [24]. Figure 1, is a female 
patient with adverse cutaneous reaction from 
Trimethoprim-Sulfamethoxazole prescribed for an 
upper respiratory tract infection. 
 
Figure 1: Patient with SJS/TEN caused by Trimethoprim -
Sulfamethoxazole, before the commencement of therapy 
 
Aminopenicillins: Aminopenicillins have been 
shown to be the most frequent causes of SJS when 
compared to the other antibiotics. This could be due to 
how frequently they are prescribed [25]. 
Amoxicillin/clavulanic acid (Co-amoxiclav) even 
resulted in SJS in an 18-month-old child treated post-
caustic poisoning and esophagogastric necrosis [26]. 
Fluoroquinolones: Ciprofloxacin induced SJS 
in a patient treated for otitis media reported in 
Sweden. [27] Norfloxacin induced SJS may appear 
similar to pemphigus, hence making early diagnosis a 
bit difficult [28]. 
Tetracyclines: Doxycycline has been 
implicated in the aetiology of SJS in the systemic use 
of ophthalmologic eyelid and ocular surface disorders 
[29]. Minocycline has been shown to induce both SJS 
and concurrent bilateral Parotitis in a young boy [30]. 
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Macrolides: Azithromycin has been shown to 
cause SJS after a five-day outpatient completion [31]. 
Cephalosporins: Cefotaxime has been 
implicated in causing SJS when administered to an 
elderly lady for treatment of upper urinary infection 
[32], likewise Cefepime [33]. 
Metronidazole: Metronidazole induced SJS 
tends to start off with neurological manifestations 
before mucocutaneous and skin eruptions. This is 
worth noting, as patients should be advised of the 
early symptoms to prevent this rare adverse effect 
[34]. 
 
Anticonvulsants 
Phenytoin: There is a possible association 
between the HLA-B*1502 allele and phenytoin-
induced SJS in Asian patients. This is still under 
review by the FDA. This could mean a possible 
genetic predisposition to getting SJS in certain 
populations as opposed to others [35]. 
Lamotrigine: A potential rare side effect of 
SJS/TEN has been implicated regardless of 
appropriate dosing and adjustments; Concurrent use 
with Valproic acid increases risk [36]. 
Carbamazepine: Increased frequency of its 
use for pain control has further increased its 
implication in causing SJS/TEN [37]. 
Oxcarbazepine: A case was reported in India 
after use for treatment of epilepsy in a 21 – year-old 
male. SJS occurred 2 weeks during treatment despite 
accurate titrations [38]. 
Phenobarbital: Risk increases within the first 2 
months of treatment. Genetic predisposition has been 
associated with this medication in conjunction with 
SJS/TEN [39]. 
Sodium valproate: A potential cause of 
SJS/TEN, though lower risk than the rest of the 
anticonvulsants. Increased risk when used together 
with other anticonvulsants. When used as 
monotherapy, it rarely causes SJS. However, if it 
occurs, it seems to be restricted to the involvement of 
only the oral mucosa [40]. 
Levetiracetam: It has been implicated in 
hypersensitivity syndrome reactions as well as SJS. 
Although rare it can be probably dose related [41]. 
 
Sulfonylureas 
Glipizide: A study showed the increase in 
dosage from 5mg to 10 mg in a certain patient 
triggered a complex immune reaction that resulted in 
SJS the following day, it was postulated it could be 
due to the certain delayed immune reaction and 
possibly due to hapten hypothesis [42]. 
 
Diuretics 
Furosemide: A potential adverse effect is 
SJS, especially when used as an additive with other 
sulfa-containing drugs [43]. 
Acetazolamide: A commonly used drug in 
ophthalmology. It is also a sulfonamide as well as a 
carbonic anhydrase inhibitor. It’s been associated with 
fatal SJS in patients of Korean and Japanese 
descents. HLA-B59, which is specific to Japanese 
descents, is a risk factor [44]. 
 
Analgesics 
i) Non-steroidal anti-inflammatory 
drugs (NSAIDS): 
Diclofenac: It could cause SJS especially in 
the elderly; caution should be applied when 
prescribing this drug [45]. 
Ibuprofen: SJS occurred in a Nepali male 
after taking 400mg of Ibuprofen every 8 hours for 
2days. It could be due to genetic predisposition by 
HLA type or some inflammatory mediators causing 
epithelial damage [46]. 
Rofecoxib: A selective COX-2 inhibitor that 
has decreased gastrointestinal side effects was 
shown to cause SJS after three weeks of 
administration to a patient with systemic arthralgia 
[47]. 
ii) Paracetamol (Acetaminophen):  
Paracetamol was shown to cause SJS/TEN 
despite its fair safety margin. It was shown to be dose-
dependent in causing SJS [48]. 
 
Antidepressants 
Mirtazapine: A patient with Systemic lupus 
erythematosus (SLE) who took mirtazapine for 
depression presented with SJS after 15 days of use. 
Though a very rare cause of SJS. The presence of the 
autoimmune disease led to a dilemma between either 
SLE or mirtazapine as the cause. The history and 
resolution of the disease eventually pointed to 
Mirtazapine as the culprit [49]. 
Duloxetine: The study showed 0.01% of 
patients treated with this medication could potentially 
cause SJS. An adolescent was affected in this study; 
so far it had only been adults involved [50]. 
 
Tyrosine kinase inhibitors 
Afatinib: SJS can be seen in patients treated 
with Afatinib for Non-small cell lung cancer (NSCLC) 
[51]. 
Vandetanib: Also used in the treatment of 
NSCLC, was shown to cause SJS in certain patients 
Fakoya et al. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis 
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[52]. 
Imatinib: SJS occurred in a patient treated 
with Imatinib for chronic myeloid leukaemia after 
treatment for 2 days. Caution should be taken in the 
prescription of this medication, as SJS is a potential 
adverse effect [53]. 
Sunitinib: A patient was treated with Sunitib 
for renal cell carcinoma with metastasis to the lung. 
On day 14 of treatment, the patient presented with 
SJS [54]. 
 
Xanthine oxidase inhibitor 
Allopurinol: Commonly used in the treatment 
of chronic gout. It is usually considered a safe drug, 
and due to its frequent administration, increased risk 
for SJS/TEN is possible, also common in genetically 
predisposed patients especially in the Han Chinese 
population [55]. 
 
Androgenic hormones 
Danazol: A patient diagnosed with systemic 
lupus erythematosus was prescribed danazol for 
treatment of autoimmune hemolytic anaemia. It has 
been approved as a second line agent in SLE related 
haematological disorders including thrombocytopenia 
[56]. 
Androgenic anabolic steroids: An athlete 
involved in the illicit use of steroids presented with 
SJS immediately after injecting drostanolone 
propionate, danazol, and metenolone enanthate [57]. 
Considering the common use of steroids for body 
performance, patients should be alerted to this rare 
side effect. 
 
Antineoplastic drugs  
Paclitaxel: An antineoplastic agent used to 
treat several cancers; Though SJS could be a rare 
complication, caution is advised when prescribed. A 
53 – year-old male treated with Paclitaxel manifested 
symptoms after administration of second dose [58]. 
Docetaxel: Due to its strong toxicity, a patient 
presented with SJS after its use as a 
chemotherapeutic agent. Skin eruptions erupted after 
the first cycle of chemotherapy [59]. 
Tegafur/gimeracil/uracil (TS-1): A 78-year-old 
Japanese male presented with SJS eight days after 
treatment for carcinoma of the oral floor. Further tests 
showed an association between drug eruptions and 
antinuclear antibodies and positive drug-induced 
lymphocyte stimulation test [DLST] [60]. 
 
Anti viral drugs 
i) Neuraminidase inhibitor (Oseltamivir); 
the medication is popularly known as Tamiflu and is 
indicated for prevention and treatment of Influenza. 
Considering the increased use of this drug, there are 
concerns about an increased risk for SJS [61]. 
ii) Nucleoside reverse transcriptase 
inhibitor (Adefovir): Commonly used in the treatment 
of Hepatitis B and Herpes simplex virus. A case of 
SJS was reported due to adefovir use [62]. 
iii) Non-nucleoside reverse transcriptase 
inhibitor (Nevirapine): Commonly used in the 
combination treatment for HIV. Patients infected with 
HIV-1 are more prone to SJS [63]. Figure 2 shows a 
healing adverse cutaneous reaction from Nevirapine 
(a component of the HAART) for a patient diagnosed 
with HIV.  
 
Figure 2: Patient with SJS/TEN caused by Nevirapine responding to 
therapy 
 
Aggrenox 
This is a combination of Aspirin and 
Dipyridamole, it is mainly used for stroke reduction in 
high-risk patients. It caused SJS in an elderly Chinese 
woman with transient ischemic attack who was 
recently switched from aspirin to Aggrenox [64]. 
 
Immunosuppressants/immunomodulators 
i) Immuno-modulatory imide drugs 
(IMiDs): 
Thalidomide: This is approved for use in the 
treatment of multiple myeloma. It inhibits Interleukin 6 
(IL-6), a vital component in the proliferation of 
myeloma cells. A study once showed thalidomide 
could be used to treat SJS/TENS. However a case of 
SJS was reported with its use. This contradiction is 
worth noting [65]. 
Lenalidomide: Though similar to thalidomide, 
it has shown to have lesser adverse effects. A rare 
adverse effect is SJS [66]. 
ii) Imidazole nucleoside: 
Mizoribine: An immunosuppressant used in 
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renal transplants, lupus nephritis and rheumatoid 
arthritis. A 32-year-old Japanese woman diagnosed 
with SLE was started on mizoribine for lupus nephritis. 
She desired pregnancy hence cyclophosphamide was 
not used. Mizoribine induced SJS 6 months later 
despite its known safety margin [67]. 
  
Antihistamines 
Fexofenadine: Telfast-D a drug containing 
both fexofenadine-pseudoephedrine was prescribed 
to a patient due to unrelenting allergic rhinitis. It 
further resulted in SJS. It was confirmed by skin 
testing (prick, intradermal and patch) which showed a 
positive reaction 96 hours later [68]. 
 
Angiotensin-converting enzyme inhibitors 
Ramipril: Ramipril resulted in SJS after being 
newly prescribed for a patient for hypertension. ACE 
inhibitors are known to interfere directly with cell 
cohesion causing bullous eruptions, which are similar 
to pemphigus vulgaris or bullous pemphigoid. These 
reactions are usually non-immunological [69]. 
 
Antiosteoporotic agent 
Strontium ranelate: It is known as a dual 
action bone agent (DABA) because of increases 
deposition of bone by osteoblasts and decreases 
resorption of bone by osteoclasts. A 67-year-old 
Chinese woman was diagnosed with SJS 3 weeks 
after starting this medication for treatment of post-
menopausal osteoporosis [70]. 
 
Other reported non-therapeutic 
agents/chemicals in the aetiology of SJS 
Iopentol: This is a contrast medium. A 6year 
old diagnosed with Hodgkin’s disease was injected 
with iopentol to undergo CT scan to explore his 
lymphadenopathy. Three days later he presented with 
SJS [71]. Knowing how common CT scans are used, 
it is worth noting the potential adverse effect of 
contrast medium.  
Carbamate: This is an insecticide. A 63 – 
year-old farmer was exposed to the insecticide two 
days before presenting with SJS. He wasn’t on any 
medication. He admitted to contact of the carbamate 
with his skin [72]. There has been a reported case of 
TENS associated with oral ingestion of carbamate as 
a suicide attempt [73].  
 
The therapeutic approach to SJS and 
TENS 
The treatment modality employed in patient 
management is dependent on the aetiology of the 
disease which as previously mentioned could be; 
infectious, drug-induced, as well as malignancies or 
idiopathic [74]. 
The first step to the treatment of SJS and 
TENS is to eliminate the causative factor. In cases of 
SJS/TENS caused by infections with organisms, the 
patient is treated with the appropriate antimicrobial. 
For drug-induced SJS/TENS, the offending drug is 
withdrawn immediately [75]. 
The next step is the provision of supportive 
care for the patient. This includes administration of 
intravenous fluids as well as parenteral or nasogastric 
feeding. Patients are also to be kept in a warm 
environment [76]. 
The final step is symptomatic treatment. 
Several methods have been employed in symptomatic 
treatment (Table 3). 
Table 3: Various approaches in the management of SJS and 
TEN 
Therapy Mechanism of Action Advantages Disadvantages Reference 
Systemic 
Corticosteroids 
They decrease 
immune response to 
an exogenous agent. 
Since SJS/TEN is 
thought to be as a 
result of an immune 
response of the 
body to an 
exogenous agent, 
corticosteroids may 
decrease the 
severity of this 
response. 
Corticosteroids are 
possible causative factors 
for SJS/TENS. Some 
studies show that they can 
increase the risk of 
infections. 
 
 
 
[77, 78] 
Human 
Intravenous 
Immune Globulin 
(IVIG) 
In addition to a 
combination of 
immunoglobulins, IVIG 
contains 
autoantibodies against 
Fas receptors. Fas 
receptors are on the 
surface of 
keratinocytes. When 
bound to by the Fas 
ligand they mediate 
the Fas-Fas ligand-
mediated apoptosis. 
The autoantibodies in 
IVIG bind to Fas 
receptors to prevent 
this apoptotic process 
Autoantibodies in 
IVIG are believed to 
reduce 
complications of 
TEN. It can be used 
in combination with 
corticosteroids as 
management 
therapy resulting in 
a better chance of 
decreasing mortality 
rate. It was 
discovered that 
when compared to 
supportive care 
only, early 
intervention with 
IVIG appeared to 
significantly improve 
the ocular 
involvement of 
SJS/TEN. 
Some studies record 
higher mortality rates with 
the use of IVIG when 
compared to supportive 
care or corticosteroids 
[77, 78] 
Cyclosporine It inhibits calcineurin 
and thus decreases T 
cell activity. It acts as 
an 
immunosuppressant. It 
can also prevent the 
process of apoptosis 
through the 
downregulation of NF-
kB. 
Patients treated 
with cyclosporine 
completed re-
epithelization more 
quickly than with 
other treatments. 
Fewer numbers of 
patients treated 
developed organ 
failure and died 
than with other 
treatments. 
Leukoencephalopathy, 
neutropenia, pneumonia, 
and nephropathy. 
[77, 79, 80] 
Plasmapheresis This process involves 
the filtration the 
patient’s blood. 
 
-The cellular 
component is 
separated, and the 
plasma is discarded. 
 
-Artificial plasma and 
albumin is added to 
the filtered cellular 
components and then 
re-transfused back into 
the patient. 
 
-This is done to 
eliminate the non-
dialyzable pathogens 
in the plasma. 
- It is a safe 
procedure. 
 
-it has yielded 
favourable results 
with survival rates 
of 77-100% after 1 
to 8 exchanges. 
 [78] 
Granulocyte 
Colony 
Stimulating Factor 
-It increases neutrophil 
counts. 
-It can reduce the 
risk of infection in 
neutropenic patients 
with SJS/TEN. 
 [77] 
 
 
Other potential therapeutic measures like the 
TNF-alpha inhibitor, thalidomide and 
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Cyclophosphamide have been associated with 
increased mortality [77]. 
In conclusion, SJS and TEN are both life 
threatening adverse hypersensitivity reactions. Proper 
understanding of the etiology as well as the 
progression of these conditions is necessary for early 
diagnosis as well as treatment. It is expected that the 
investigation of the mechanism of action of drugs 
associated with SJS and TEN will improve the current 
understanding of the condition with aim of eliminating 
its incidence. There are existing treatment modalities 
for these conditions, however, there is no therapeutic 
measure defined as superior to others. It has however 
been observed that the earlier these conditions are 
diagnosed and managed the better the prognosis. 
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